- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07724548
Comparison Between Virtual vs in Person on Treatment Follow-up Visits of Radiotherapy
Transforming On-Treatment Follow-Up Care: A Randomized Controlled Trial of Virtual Versus In-Person Visits Evaluating Clinical Outcomes, Patient-Reported Measures, and Telehealth Implementation
Panoramica dello studio
Stato
Condizioni
Descrizione dettagliata
Telemedicine and telehealth services, operationally defined as patient-provider interactions conducted through telecommunication technologies, have experienced widespread integration across diverse medical specialties. Prior to the onset of the coronavirus disease 2019 (COVID-19) pandemic, numerous clinical disciplines had adopted telemedicine modalities to enhance healthcare accessibility and improve patient convenience. The COVID-19 pandemic and its aftermath have precipitated an unprecedented acceleration in the adoption of telehealth services, profoundly reshaping healthcare delivery paradigms across multiple disciplines.
As of 2025, Pakistan continues to grapple with a substantial cancer burden, with more than 185,000 new cases and over 125,000 cancer-related deaths reported annually. Despite ongoing efforts to improve awareness, early detection, and treatment accessibility, major challenges persist-particularly regarding healthcare access in rural regions and the financial burden associated with cancer treatment. For patients undergoing primary treatment, the costs of travel, accommodation, and sustenance during treatment and follow-up visits constitute significant barriers. These economic constraints frequently result in missed appointments and treatment discontinuation, thereby compromising the effectiveness of established therapeutic protocols.
Addressing these barriers necessitates a multifaceted approach, including the strategic expansion of telemedicine services. Telehealth can serve as a vital tool to bridge gaps in cancer care accessibility, ensuring that patients receive timely and continuous treatment regardless of geographic location or socioeconomic status.
Shaukat Khanum Memorial Cancer Hospital and Research Centre (SKMCH&RC) is a leading institution in Pakistan, delivering comprehensive oncologic care to a large patient population. In 2024 alone, approximately 83,000 patients received radiotherapy in neoadjuvant, adjuvant, or palliative settings, underscoring the hospital's pivotal role in cancer management. As a high-volume cancer center, effective coordination of follow-up appointments and the maintenance of accurate clinical documentation are essential tasks that require seamless collaboration between patients and healthcare professionals.
Patients undergoing radiation therapy at SKMCH&RC were consecutively recruited and randomly assigned to either a hybrid follow-up group, receiving one virtual and one in-person appointment, or a control group receiving only in-person follow-ups. Clinical and demographic information was obtained from patient records. Following each visit, patients completed an anonymous, validated questionnaire survey assessing satisfaction, communication, and convenience. Additional logistical data, including appointment adherence, visit duration, and any technical difficulties during virtual visits, were systematically documented. All collected data were anonymized and stored securely to maintain confidentiality and support robust analysis of telehealth integration in on-treatment care.
Tipo di studio
Iscrizione (Stimato)
Contatti e Sedi
Contatto studio
- Nome: Anusha Haider, MBBS
- Numero di telefono: 4072 03244534247
- Email: anushahaider@skm.org.pk
Backup dei contatti dello studio
- Nome: Sadia Anjum, MBBS
- Numero di telefono: 4072 03280117652
- Email: sadianjum@skm.org.pk
Luoghi di studio
-
-
Punjab Province
-
Lahore, Punjab Province, Pakistan
- Reclutamento
- Shaukat Khanum Memorial Cancer hospital & Research Centre
-
Contatto:
- Farah Asif, MBBS
- Numero di telefono: 4280 04235905000
- Email: crc3@skm.org.pk
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
- Adulto
- Adulto più anziano
Accetta volontari sani
Metodo di campionamento
Popolazione di studio
Descrizione
Inclusion Criteria:
- Patients who are 18 years and above.
- All patients who are undergoing radiotherapy (>5 fractions).
- Capacity to provide informed consent for participation in the study.
Exclusion Criteria:
- Patients below 18 years
- Unable to provide informed consent for participation in the study.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
Coorti e interventi
Gruppo / Coorte |
|---|
|
Inperson followup visits
Group A involves weekly in person followup visits in radiation department undergoing radiotherapy.
|
|
Hybrid virtual & inperson radiotherpay followup
Group B involves hybrid group with alternating 1 virtual and 1 in person followup visits in radiation department undergoing radiotherapy.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Outcomes of virtual vs in person on treatment of follow-up radiotherapy visits through structured questionnaire
Lasso di tempo: 4 weeks
|
To evaluate the implementation of virtual and in person follow-up visits thereby accessing and comparing patient satisfaction with both modalities through structured questionnaire providing insights into clinical utility and overall acceptability of telehealth integration during active cancer treatment.
|
4 weeks
|
Collaboratori e investigatori
Pubblicazioni e link utili
Pubblicazioni generali
- Latif A, Usmani S, Sheikh A, et al. Bridging oncology gaps with telemedicine in low-resource settings. J Glob Oncol. 2023;9:1-8.
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Altri numeri di identificazione dello studio
- IRB-25-1
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .